u/Tom_2772

As of October 1, 2026, UHC explicitly lists LYTENAVA™ (bevacizumab-vikg) in its new-to-market “Review at Launch” process for provider-administered medical-benefit drugs.

This applies to UnitedHealthcare Commercial and Community Plan.

With more than 30 million people served through its Commercial business, UHC is a major U.S. payer.

Another important step in the U.S. commercialization and reimbursement infrastructure for LYTENAVA.

Source: UnitedHealthcare Provider, October 2026 Medical Benefit Drug / Specialty Medical Injectable updates.

https://www.uhcprovider.com/content/dam/provider/docs/public/resources/news/2026/sdub/med-benefit-specialty-drug-update-bulletin-october-2026.pdf

Just a thought experiment… This is an older Reuters article from May 1, 2026, but an interesting one. Reuters reported that Big Pharma was becoming more risk-on with M&A, particularly in deals under $10B, as upcoming patent expiries create urgency. With an $8.5B U.S. market alone, before even considering the UK and EU, and 12 years of exclusivity, I think there’s definitely something worth thinking about here. Nobody knows what Big Pharma or competitors might be planning. Just food for thought.

https://www.reuters.com/legal/transactional/big-pharma-ma-set-mega-year-patent-expiries-drive-deal-urgency-2026-05-01/